title: Clinical correlations with Porphyromonas gingivalis antibody responses in patients with early rheumatoid arthritis.
abstract: BACKGROUND
  Prior studies have demonstrated an increased frequency of antibodies to Porphyromonas gingivalis (Pg), a leading agent of periodontal disease, in rheumatoid arthritis (RA) patients. However, these patients generally had long-standing disease, and clinical associations with these antibodies were inconsistent. Our goal was to examine Pg antibody responses and their clinical associations in patients with early RA prior to and after disease-modifying antirheumatic drug (DMARD) therapy.
  
  
  METHODS
  Serum samples from 50 DMARD-naïve RA patients were tested using an enzyme-linked immunosorbent assay with whole-Pg sonicate. For comparison, serum samples were tested from patients with late RA, patients with other connective tissue diseases (CTDs), age-similar healthy hospital personnel and blood bank donors. Pg antibody responses in early RA patients were correlated with standard RA biomarkers, measures of disease activity and function.
  
  
  RESULTS
  At the time of enrollment, 17 (34%) of the 50 patients with early RA had positive immunoglobulin G (IgG) antibody responses to Pg, as did 13 (30%) of the 43 patients with late RA. RA patients had significantly higher Pg antibody responses than healthy hospital personnel and blood bank donors (P < 0.0001). Additionally, RA patients tended to have higher Pg antibody reactivity than patients with other CTDs (P = 0.1), and CTD patients tended to have higher Pg responses than healthy participants (P = 0.07). Compared with Pg antibody-negative patients, early RA patients with positive Pg responses more often had anti-cyclic citrullinated peptide (anti-CCP) antibody reactivity, their anti-CCP levels were significantly higher (P = 0.03) and the levels of anti-Pg antibodies correlated directly with anti-CCP levels (P < 0.01). Furthermore, at the time of study entry, the Pg-positive antibody group had greater rheumatoid factor values (P = 0.04) and higher inflammatory markers (erythrocyte sedimentation rate, or ESR) (P = 0.05), and they tended to have higher disease activity scores (Disease Activity Score based on 28-joint count (DAS28)-ESR and Clinical Disease Activity Index) and more functional impairment (Health Assessment Questionnaire). In Pg-positive patients, greater disease activity was still apparent after 12 months of DMARD therapy.
  
  
  CONCLUSIONS
  A subset of early RA patients had positive Pg antibody responses. The responses correlated with anti-CCP antibody reactivity and to a lesser degree with ESR values. There was a trend toward greater disease activity in Pg-positive patients, and this trend remained after 12 months of DMARD therapy. These findings are consistent with a role for Pg in disease pathogenesis in a subset of RA patients.
authors.forename: Sheila L
authors.initials: SL
authors.lastname: Arvikar
authors.forename: Deborah S
authors.initials: DS
authors.lastname: Collier
authors.forename: Mark C
authors.initials: MC
authors.lastname: Fisher
authors.forename: Sebastian
authors.initials: S
authors.lastname: Unizony
authors.forename: George L
authors.initials: GL
authors.lastname: Cohen
authors.forename: Gail
authors.initials: G
authors.lastname: McHugh
authors.forename: Toshihisa
authors.initials: T
authors.lastname: Kawai
authors.forename: Klemen
authors.initials: K
authors.lastname: Strle
authors.forename: Allen C
authors.initials: AC
authors.lastname: Steere
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000907:Antibodies, Bacterial / Q000097:blood / Q000276:immunology*; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000276:immunology* / Q000382:microbiology; D001323:Autoantibodies / Q000097:blood / Q000276:immunology; D016866:Bacteroidaceae Infections / Q000097:blood / Q000276:immunology* / Q000382:microbiology; D015415:Biomarkers / Q000097:blood; D001799:Blood Sedimentation; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D054884:Host-Pathogen Interactions / Q000187:drug effects / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000276:immunology; D016966:Porphyromonas gingivalis / Q000276:immunology* / Q000502:physiology; D013997:Time Factors; D055815:Young Adult
chemical_list: D000907:Antibodies, Bacterial; D018501:Antirheumatic Agents; D001323:Autoantibodies; D015415:Biomarkers; D007074:Immunoglobulin G; D010456:Peptides, Cyclic; C487763:cyclic citrullinated peptide
references.citation: J Periodontol. 2011 Aug;82(8):1140-5
references.pmid: 21815717
references.citation: Ann Rheum Dis. 2014 Jan;73(1):263-9
references.pmid: 23463691
references.citation: J Clin Periodontol. 1998 Jun;25(6):510-6
references.pmid: 9667485
references.citation: Arthritis Rheum. 2009 Apr 15;61(4):488-94
references.pmid: 19333976
references.citation: J Clin Periodontol. 2011 Jun;38(6):532-41
references.pmid: 21434962
references.citation: J Clin Periodontol. 2012 Jul;39(7):599-607
references.pmid: 22530757
references.citation: J Clin Periodontol. 2011 May;38(5):405-11
references.pmid: 21362013
references.citation: Infect Immun. 1991 Dec;59(12):4363-70
references.pmid: 1682261
references.citation: Arthritis Rheum. 2008 Oct;58(10):3009-19
references.pmid: 18821669
references.citation: J Periodontol. 2009 Apr;80(4):535-40
references.pmid: 19335072
references.citation: J Clin Periodontol. 1999 Feb;26(2):77-84
references.pmid: 10048640
references.citation: Arthritis Rheum. 2011 Dec;63(12):3818-23
references.pmid: 21953289
references.citation: Ann Rheum Dis. 2012 Sep;71(9):1541-4
references.pmid: 22875903
references.citation: Inflammation. 2013 Jun;36(3):665-9
references.pmid: 23296876
references.citation: Arthritis Rheum. 2012 Oct;64(10):3083-94
references.pmid: 22576262
references.citation: J Periodontol. 2004 Jan;75(1):16-22
references.pmid: 15025212
references.citation: Arthritis Rheum. 2012 Nov;64(11):3522-30
references.pmid: 22736291
references.citation: J Periodontol. 2011 Oct;82(10):1433-41
references.pmid: 21342003
references.citation: Arthritis Res Ther. 2012 Oct 17;14(5):R222
references.pmid: 23075462
references.citation: Ann Rheum Dis. 2004 Sep;63(9):1090-5
references.pmid: 15308518
references.citation: J Periodontol. 2008 Jun;79(6):979-86
references.pmid: 18533773
references.citation: MedGenMed. 2005 Jun 16;7(2):2
references.pmid: 16369381
references.citation: J Periodontol. 2010 Oct;81(10):1379-89
references.pmid: 20450376
references.citation: Inflammation. 2004 Dec;28(6):311-8
references.pmid: 16245073
references.citation: Clin Vaccine Immunol. 2009 Dec;16(12):1766-73
references.pmid: 19793900
references.citation: J Rheumatol. 2008 Jan;35(1):70-6
references.pmid: 18050377
references.citation: Ann Intern Med. 2007 Jun 5;146(11):797-808
references.pmid: 17548411
references.citation: Arthritis Rheum. 2004 Feb;50(2):380-6
references.pmid: 14872479
references.citation: Arthritis Rheum. 2010 Sep;62(9):2662-72
references.pmid: 20506214
references.citation: Rheumatology (Oxford). 2007 Jan;46(1):70-5
references.pmid: 16782731
references.citation: Ann Rheum Dis. 2008 Dec;67 Suppl 3:iii26-9
references.pmid: 19022809
references.citation: J Rheumatol. 2010 Jun;37(6):1105-12
references.pmid: 20436074
references.citation: Arthritis Rheum. 2013 Jan;65(1):167-73
references.pmid: 23055204
references.citation: J Clin Periodontol. 2002 Feb;29(2):92-102
references.pmid: 11908470
references.citation: Arthritis Rheum. 2010 Sep;62(9):2569-81
references.pmid: 20872595
references.citation: J Autoimmun. 2012 Dec;39(4):294-303
references.pmid: 22560973
references.citation: Int Immunopharmacol. 2009 Jan;9(1):38-42
references.pmid: 18848647
references.citation: Ann Rheum Dis. 2006 Jul;65(7):905-9
references.pmid: 16284099